top of page

GSK and Janssen seek European approval for sirukumab in rheumatoid arthritis

GlaxoSmithKline (GSK) and Janssen-Cilag International have submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for the approval of sirukumab to treat moderately to severely active rheumatoid arthritis (RA) in adults.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page